BACKGROUND: Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than for any other medical condition. With the aging of the population, the impact of HF is expected to increase substantially. METHODS AND RESULTS: We estimated future costs of HF by adapting a methodology developed by the American Heart Association to project the epidemiology and future costs of HF from 2012 to 2030 without double counting the costs attributed to comorbid conditions. The model assumes that HF prevalence will remain constant by age, sex, and race/ethnicity and that rising costs and technological innovation will continue at the same rate. By 2030, >8 million people in the United States (1 in every 33) will have HF. Between 2012 and 2030, real (2010$) total direct medical costs of HF are projected to increase from $21 billion to $53 billion. Total costs, including indirect costs for HF, are estimated to increase from $31 billion in 2012 to $70 billion in 2030. If one assumes all costs of cardiac care for HF patients are attributable to HF (no cost attribution to comorbid conditions), the 2030 projected cost estimates of treating patients with HF will be 3-fold higher ($160 billion in direct costs). CONCLUSIONS: The estimated prevalence and cost of care for HF will increase markedly because of aging of the population. Strategies to prevent HF and improve the efficiency of care are needed.
BACKGROUND:Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than for any other medical condition. With the aging of the population, the impact of HF is expected to increase substantially. METHODS AND RESULTS: We estimated future costs of HF by adapting a methodology developed by the American Heart Association to project the epidemiology and future costs of HF from 2012 to 2030 without double counting the costs attributed to comorbid conditions. The model assumes that HF prevalence will remain constant by age, sex, and race/ethnicity and that rising costs and technological innovation will continue at the same rate. By 2030, >8 million people in the United States (1 in every 33) will have HF. Between 2012 and 2030, real (2010$) total direct medical costs of HF are projected to increase from $21 billion to $53 billion. Total costs, including indirect costs for HF, are estimated to increase from $31 billion in 2012 to $70 billion in 2030. If one assumes all costs of cardiac care for HF patients are attributable to HF (no cost attribution to comorbid conditions), the 2030 projected cost estimates of treating patients with HF will be 3-fold higher ($160 billion in direct costs). CONCLUSIONS: The estimated prevalence and cost of care for HF will increase markedly because of aging of the population. Strategies to prevent HF and improve the efficiency of care are needed.
Entities:
Keywords:
AHA Scientific Statements; heart failure
Authors: Samuel S Gidding; Alice H Lichtenstein; Myles S Faith; Allison Karpyn; Julie A Mennella; Barry Popkin; Jonelle Rowe; Linda Van Horn; Laurie Whitsel Journal: Circulation Date: 2009-03-03 Impact factor: 29.690
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: Circulation Date: 2009-03-26 Impact factor: 29.690
Authors: Donald M Lloyd-Jones; Yuling Hong; Darwin Labarthe; Dariush Mozaffarian; Lawrence J Appel; Linda Van Horn; Kurt Greenlund; Stephen Daniels; Graham Nichol; Gordon F Tomaselli; Donna K Arnett; Gregg C Fonarow; P Michael Ho; Michael S Lauer; Frederick A Masoudi; Rose Marie Robertson; Véronique Roger; Lee H Schwamm; Paul Sorlie; Clyde W Yancy; Wayne D Rosamond Journal: Circulation Date: 2010-01-20 Impact factor: 29.690
Authors: Michael R Zile; William H Gaasch; Inder S Anand; Markus Haass; William C Little; Alan B Miller; Jose Lopez-Sendon; John R Teerlink; Michel White; John J McMurray; Michel Komajda; Robert McKelvie; Agata Ptaszynska; Scott J Hetzel; Barry M Massie; Peter E Carson Journal: Circulation Date: 2010-03-15 Impact factor: 29.690
Authors: Marvin A Konstam; Mariell Jessup; Gary S Francis; Douglas L Mann; Barry Greenberg Journal: J Am Coll Cardiol Date: 2009-03-10 Impact factor: 24.094
Authors: Bruce Leff; Lisa Reider; Kevin D Frick; Daniel O Scharfstein; Cynthia M Boyd; Katherine Frey; Lya Karm; Chad Boult Journal: Am J Manag Care Date: 2009-08 Impact factor: 2.229
Authors: Gordon R Reeves; David J Whellan; Pamela Duncan; Christopher M O'Connor; Amy M Pastva; Joel D Eggebeen; Leigh Ann Hewston; Timothy M Morgan; Shelby D Reed; W Jack Rejeski; Robert J Mentz; Paul B Rosenberg; Dalane W Kitzman Journal: Am Heart J Date: 2016-12-28 Impact factor: 4.749
Authors: Matteo Fabbri; Kathleen Yost; Lila J Finney Rutten; Sheila M Manemann; Cynthia M Boyd; Daniel Jensen; Susan A Weston; Ruoxiang Jiang; Véronique L Roger Journal: Mayo Clin Proc Date: 2017-12-06 Impact factor: 7.616
Authors: Leor Perl; Elina Soifer; Jozef Bartunek; Dedi Erdheim; Friedrich Köhler; William T Abraham; David Meerkin Journal: J Cardiovasc Transl Res Date: 2019-01-02 Impact factor: 4.132
Authors: Catherine N Marti; Hassan Khan; Douglas L Mann; Vasiliki V Georgiopoulou; Kirsten Bibbins-Domingo; Tamara Harris; Annemarie Koster; Anne Newman; Stephen B Kritchevsky; Andreas P Kalogeropoulos; Javed Butler Journal: Circ Heart Fail Date: 2013-12-09 Impact factor: 8.790
Authors: Emily C Gathright; Mary A Dolansky; John Gunstad; Joseph D Redle; Richard A Josephson; Shirley M Moore; Joel W Hughes Journal: Health Psychol Date: 2017-07-20 Impact factor: 4.267
Authors: Horng H Chen; Omar F AbouEzzeddine; Kevin J Anstrom; Michael M Givertz; Bradley A Bart; G Michael Felker; Adrian F Hernandez; Kerry L Lee; Eugene Braunwald; Margaret M Redfield Journal: Circ Heart Fail Date: 2013-09-01 Impact factor: 8.790